AstraZeneca: milestone triggers payment to Japan's Sosei

(CercleFinance.com) - AstraZeneca has reached a clinical development milestone with Sosei Heptares' next generation immuno-oncology candidate drug, AZD4635, triggering a 15 million dollar payment to the Japanese biopharmaceutical company.


The oral drug - discovered by Sosei and licensed to AstraZeneca - has been advancing through a Phase 1 clinical program, both as a single agent, and in combination with AstraZeneca's anti-PD-L1 antibody durvalumab, in patients with solid tumours.

AstraZeneca is now moving the trial towards Phase 2.

Separately, US diagnostics company Chembio has received a CE mark for its test developed in collaboration with AstraZeneca providing results in ten minutes from a small drop of blood.

Copyright (c) 2019 CercleFinance.com. All rights reserved.